Creative Planning Denali Therapeutics Inc. Transaction History

Creative Planning

$129 Billion
Q3 2025

A detailed history of Creative Planning transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Creative Planning holds 54,834 shares of DNLI stock, worth $956,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,834

Previous 57,678 4.93%

Holding current value

$956,304

Previous $806,000 1.24%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$12.75 - $15.65 $36,261 - $44,508	-2,844 Reduced 4.93%	54,834 $796,000
Q2 2025 Aug 08, 2025	BUY	$11.47 - $16.65 $310,997 - $451,448	27,114 Added 88.71%	57,678 $806,000
Q1 2025 May 15, 2025	SELL	$13.6 - $23.59 $236,449 - $410,135	-17,386 Reduced 36.26%	30,564 $415,000
Q4 2024 Feb 14, 2025	SELL	$20.24 - $31.58 $249,032 - $388,560	-12,304 Reduced 20.42%	47,950 $977,000
Q3 2024 Oct 11, 2024	BUY	$20.96 - $31.05 $360,952 - $534,712	17,221 Added 40.02%	60,254 $1.76 Million

Q2 2024 Aug 15, 2024	BUY	$14.96 - $23.22 $51,731 - $80,294	3,458 Added 8.74%	43,033 $999,000
Q1 2024 May 10, 2024	BUY	$15.83 - $23.35 $233,729 - $344,762	14,765 Added 59.51%	39,575 $812,000
Q4 2023 Feb 14, 2024	BUY	$16.2 - $23.18 $168,382 - $240,932	10,394 Added 72.1%	24,810 $532,000
Q3 2023 Nov 16, 2023	BUY	$20.63 - $30.17 $4,435 - $6,486	215 Added 1.51%	14,416 $297,000
Q2 2023 Jul 21, 2023	BUY	$23.37 - $32.96 $90,044 - $126,994	3,853 Added 37.23%	14,201 $419,000
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $63,078 - $94,056	2,879 Added 38.55%	10,348 $238,000
Q4 2022 Feb 10, 2023	BUY	$26.28 - $33.92 $4,756 - $6,139	181 Added 2.48%	7,469 $207,000
Q3 2022 Nov 03, 2022	BUY	$25.97 - $38.53 $5,531 - $8,206	213 Added 3.01%	7,288 $224,000
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $6,159 - $10,381	295 Added 4.35%	7,075 $208,000
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $45,588 - $74,308	1,572 Added 30.18%	6,780 $218,000
Q3 2021 Nov 10, 2021	BUY	$48.48 - $78.23 $252,483 - $407,421	5,208 New	5,208 $263,000
Q4 2020 Jan 29, 2021	SELL	$36.89 - $93.56 $408,741 - $1.04 Million	-11,080 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$23.13 - $38.84 $256,280 - $430,347	11,080 New	11,080 $397,000

Others Institutions Holding DNLI

# of Institutions

259

Shares Held

133M

Call Options Held

219K

Put Options Held

107K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.34B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Denali Therapeutics Inc. Transaction History